The serotonin transporter has long been a focus of studies of mood disorders because of its role as a site of antidepressants. The recent cloning of the gene and identification of a functional polymorphism have fueled a new round of intriguing results regarding the gene's role in illness. These data have suggested that a low transcriptional activity allele predisposes to mood disorder. A report by Smeraldi et al in this issue further indicates that individuals with this low activity allele are more likely to have treatment refractory illness and to respond to augmentation with the 5-HT 1A antagonist, pindolol. Together these data suggest that the low activity allele may predispose to a form of illness in which the serotonin system is inhibited through activation of somatodendritic 5-HT 1A receptors. It also provides an exciting glimpse into possible future applications of pharmacogenetics.
Through the application of new technology and methods, the field of molecular psychiatry promises new insights and advances in both the basic science and clinical management of complex behavioral disorders. It is this promise of completely new insights and applications that has driven this field and its investigators through its relatively brief history. Positional cloning studies promise the identification of novel genes and novel disease mechanisms for psychiatric disorders. Mutational and association analyses of candidate genes may provide insights into the role of known genes. Molecular methods have made possible dramatic advances in basic neuroscience. However, the area most likely to first yield practical clinical applications is molecular pharmacogenetics. In this issue, Smeraldi et al provide one of the first glimpses into such future applications of molecular psychiatry.
Approximately two-thirds of people being treated with anti-depressant medication will respond. However, for those one-third of patients who do not respond, clinicians face a series of complex choices. The patient may be switched to another medication of similar or different pharmacological category, or the first anti-depressant may be augmented by the addition of other agents including lithium, thyroid hormone, buspirone, or pindolol. It is clear from systematic data and clinical experience that some patients respond to some of these strategies and others do not. However, there is no test to predict preferential response to one strategy over the others. It is a compelling hypothesis that genetic factors may distinguish patients in this regard, and thereby, provide a powerful method to predict treatment response. Smeraldi et al demonstrate such an effect in their paper.
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As the site of action of selective serotonin re-uptake inhibitor (SSRI) antidepressants and a key regulator of serotonergic neurotransmission, the serotonin transporter (HTT) is an important candidate gene for mood disorders. Lesch et al have recently identified an insertion/deletion polymorphism in the promoter of this gene which regulates the level of its transcription. 1 Smeraldi et al explore the hypothesis that this polymorphism may play a role in the response to treatment using SSRI antidepressants. They find that subjects which are homozygous for the short form of the polymorphism, which results in lower levels of serotonin transporter mRNA, have a significantly poorer response to treatment using fluvoxamine. They further observe that this difference in treatment response disappears when fluvoxamine treatment is augmented with the 5HT 1A antagonist pindolol. If replicated, this observation could potentially provide a simple biological test to indicate which patients would benefit from pindolol augmentation.
In addition to its possible clinical utility, this observation adds an intriguing piece to the puzzle of the mechanism of action of SSRIs and the role of HTT in depression. Though its relevance to central function can be questioned, platelet HTT binding and function has long been used as a peripheral model of central serotonergic function. Platelet HTT binding has been repeatedly observed to be decreased in depressed patients. 2 Furthermore, this decrease in HTT binding reportedly normalized in patients who had a good response to antidepressant treatment. 3 However, pretreatment levels of HTT binding did not predict response to antidepressant treatment. 4, 5 The cloning of the human HTT gene and subsequent identification of several polymorphisms have permitted genomic studies of the gene in psychiatric disease. Mood disorder has been reported to be associated with both an intron 2 polymorphism of the HTT gene and the insertion/deletion polymorphism in the promoter. [6] [7] [8] In these studies, both bipolar and unipolar disorders have been associated with the short, low transcriptional activity allele. These data together with the report of Smeraldi et al form an intriguing and seemingly paradoxical story about HTT in depression. The facts seem to be: (1) the low activity allele of HTT transmits a genetic risk for depression and is associated with treatment refractory illness; (2) HTT expression is diminished in depression and normalizes with successful treatment; (3) patients with low expression of HTT are more likely to respond to pindolol augmentation. These observations raise several questions and paradoxes. Why is low HTT expression associated with depression when SSRIs, which block HTT function, treat depression? Is the dysfunction of the serotonin system different in those who are homozygotes for the HTT low activity allele?
There is an increasing consensus that depression is associated with a deficit in serotonergic neurotransmission, and that antidepressants work by improving serotonergic function. Antidepressant efficacy has been related to a post-synaptic effect of chronic treatment involving downregulation of 5HT 1A or 5HT 2 receptors. 9 However, much interest has recently been focused on pre-synaptic mechanisms including downregulation of terminal autoreceptors or somatodendritic autoreceptors. Electrophysiological and microdialysis studies of acute treatment have indicated that SSRIs lead to a decrease in the firing rate of serotonergic neurons and a decrease in serotonin release. 10 This is likely due to the inhibitory effect of increased synaptic serotonin on the somatodendritic autoreceptors. Blockade of these autoreceptors by the 5HT 1A antagonist, pindolol, prevents this acute reduction in serotonin release. This is the probable explanation for the ability of pindolol to augment SSRI treatment. Pindolol augmentation has been reported to produce a more rapid and effective antidepressant response in some, 11 but not all clinical trials.
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It is not currently clear how to assemble these facts into a comprehensive model of antidepressant action and depression. However, based on current knowledge, one can speculate several possible mechanisms. The low activity HTT allele may result in increased synaptic serotonin, thereby activating autoreceptors and inhibiting serotonin release. Individuals with this allele have a chronically inhibited serotonin system that predisposes them to depression. This requires an assumption that such an increase in synaptic serotonin would be adequate to activate autoreceptors, but not adequate to downregulate them. Individuals homozygous for the low activity allele also have fewer binding sites for SSRIs, and less capacity to increase synaptic serotonin by reuptake inhibition. Therefore, they are resistant to treatment with SSRIs, and more likely to require an augmentative treatment such as pindolol. Autoreceptor inhibition may also figure more prominently as part of these individuals' serotonergic pathology, making them more likely to benefit from pindolol. This would suggest that the serotonergic pathology is somewhat different in low activity allele homozygotes. This latter possibility raises another important aspect of pharmacogenetic studies. Genetic factors may enable us to distinguish heterogeneous mechanisms of illness and treatment response. By combining the effect of a pharmacological probe with knowledge of the genetic substrate, a more precise understanding of molecular pathology may be obtained. Clearly, much remains to be learned about serotonergic dysfunction in depression and the mechanism of action of SSRIs. The recent introduction of information about molecular genetic variation at the HTT locus has considerably enriched this already complex field. As polymorphisms at other components of the system are identified, an even more complex story is likely to emerge.
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